Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms

Majority of patients with metastatic castrate resistant prostate cancer (mCRPC) develop bone metastases which results in significant morbidity and mortality as a result of skeletal-related events (SREs). Several bone-targeted agents are either in clinical use or in development for prevention of SREs...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: El-Amm, Joelle, Freeman, Ashley, Patel, Nihar, Aragon-Ching, Jeanny B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi Publishing Corporation 2013
Gaiak:
Review Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3771418/
https://ncbi.nlm.nih.gov/pubmed/24069538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2013/210686
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak